AZD1222

Browse the articles related to this topic below.

Post author By EvidenceNotFear
Post date 20 April 2022

The risk of myocarditis in this large cohort study was highest in young males after the second SARS-CoV-2 vaccine dose, and this risk should be balanced against the benefits of protecting against severe COVID-19 disease.

https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253

Archive link: https://web.archive.org/web/20230000000000*/https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253

Publications

Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults – ClinicalTrials.gov

Post author By EvidenceNotFear
Post date 18 August 2020

Brief Summary:The aim of the study is to assess the safety, efficacy, and immunogenicity of AZD1222 for the prevention of COVID-19.

Actual Study Start Date :	August 28, 2020
Actual Primary Completion Date :	March 5, 2021
Estimated Study Completion Date :	February 14, 2023

https://clinicaltrials.gov/ct2/show/NCT04516746

Tags AstraZeneca, AZD1222, ChAdOx1, ClinicalTrials.gov, COVID-19, Pharmaceutical Industry, Randomized Controlled Trials, Vaccination